Wockhardt Q1 FY25 revenue up 14%
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Our centers are performing as expected or even better
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Subscribe To Our Newsletter & Stay Updated